These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 31733655)

  • 1. Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease.
    Henderson MX; Sengupta M; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2019 Nov; 7(1):183. PubMed ID: 31733655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
    Vilas D; Shaw LM; Taylor P; Berg D; Brockmann K; Aasly J; Marras C; Pont-Sunyer C; Ríos J; Marek K; Tolosa E
    Mov Disord; 2016 Jun; 31(6):906-14. PubMed ID: 27041685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's Disease Associated with G2019S LRRK2 Mutations without Lewy Body Pathology.
    Jackson LM; Woodruff BK; Tremblay C; Shill HA; Beach TG; Serrano GE; Adler CH
    Mov Disord Clin Pract; 2024 Jul; 11(7):874-878. PubMed ID: 38757351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LRRK2 Kinase Activity Does Not Alter Cell-Autonomous Tau Pathology Development in Primary Neurons.
    Henderson MX; Changolkar L; Trojanowski JQ; Lee VMY
    J Parkinsons Dis; 2021; 11(3):1187-1196. PubMed ID: 33720852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression.
    Lubben N; Brynildsen JK; Webb CM; Li HL; Leyns CEG; Changolkar L; Zhang B; Meymand ES; O'Reilly M; Madaj Z; DeWeerd D; Fell MJ; Lee VMY; Bassett DS; Henderson MX
    Transl Neurodegener; 2024 Mar; 13(1):13. PubMed ID: 38438877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The emerging role of LRRK2 in tauopathies.
    Herbst S; Lewis PA; Morris HR
    Clin Sci (Lond); 2022 Jul; 136(13):1071-1079. PubMed ID: 35815712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson's disease: a study in LRRK2 mutation carriers.
    Majbour NK; Aasly JO; Hustad E; Thomas MA; Vaikath NN; Elkum N; van de Berg WDJ; Tokuda T; Mollenhauer B; Berendse HW; El-Agnaf OMA
    Transl Neurodegener; 2020 May; 9(1):15. PubMed ID: 32375873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT.
    Ling H; Kara E; Bandopadhyay R; Hardy J; Holton J; Xiromerisiou G; Lees A; Houlden H; Revesz T
    Neurobiol Aging; 2013 Dec; 34(12):2889.e5-9. PubMed ID: 23664753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.
    Mamais A; Raja M; Manzoni C; Dihanich S; Lees A; Moore D; Lewis PA; Bandopadhyay R
    Neurobiol Dis; 2013 Oct; 58():183-90. PubMed ID: 23747310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology.
    Mamais A; Manzoni C; Nazish I; Arber C; Sonustun B; Wray S; Warner TT; Cookson MR; Lewis PA; Bandopadhyay R
    Brain Res; 2018 Dec; 1701():75-84. PubMed ID: 30055128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
    Henderson MX; Peng C; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Garrido A; Fairfoul G; Tolosa ES; Martí MJ; Green A;
    Ann Clin Transl Neurol; 2019 Jun; 6(6):1024-1032. PubMed ID: 31211166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological Functions of LRRK2 in Parkinson's Disease.
    Jeong GR; Lee BD
    Cells; 2020 Nov; 9(12):. PubMed ID: 33266247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease.
    Alegre-Abarrategui J; Ansorge O; Esiri M; Wade-Martins R
    Neuropathol Appl Neurobiol; 2008 Jun; 34(3):272-83. PubMed ID: 17971075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain.
    Nguyen APT; Daniel G; Valdés P; Islam MS; Schneider BL; Moore DJ
    Hum Mol Genet; 2018 Jan; 27(1):120-134. PubMed ID: 29088368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers.
    Aasly JO; Shi M; Sossi V; Stewart T; Johansen KK; Wszolek ZK; Uitti RJ; Hasegawa K; Yokoyama T; Zabetian CP; Kim HM; Leverenz JB; Ginghina C; Armaly J; Edwards KL; Snapinn KW; Stoessl AJ; Zhang J
    Neurology; 2012 Jan; 78(1):55-61. PubMed ID: 22170881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
    Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
    Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LRRK2 p.Ile1371Val Mutation in a Case with Neuropathologically Confirmed Multi-System Atrophy.
    Lee K; Nguyen KD; Sun C; Liu M; Zafar F; Saetern J; Flierl A; Tetrud JW; Langston JW; Dickson D; Schüle B
    J Parkinsons Dis; 2018; 8(1):93-100. PubMed ID: 29480226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.
    Gaig C; Ezquerra M; Martí MJ; Valldeoriola F; Muñoz E; Lladó A; Rey MJ; Cardozo A; Molinuevo JL; Tolosa E
    J Neurol Sci; 2008 Jul; 270(1-2):94-8. PubMed ID: 18353371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation.
    Giordana MT; D'Agostino C; Albani G; Mauro A; Di Fonzo A; Antonini A; Bonifati V
    Mov Disord; 2007 Jan; 22(2):275-8. PubMed ID: 17149743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.